Dose recommendations for anticancer drugs in patients with renal or hepatic impairment

2018, Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1859, 10.1016/S0140-6736(18)32335-3

Launay-Vacher, 2007, Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study, Cancer, 110, 1376, 10.1002/cncr.22904

Mathijssen, 2007, Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?, Oncologist, 12, 913, 10.1634/theoncologist.12-8-913

Peyrade, 2013, 11

Joerger, 2013, 22

Pugh, 1973, Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, 60, 646, 10.1002/bjs.1800600817

Mansfield, 2016, The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects, Clin Cancer Res, 22, 5472, 10.1158/1078-0432.CCR-16-0449

Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006

Inker, 2014, KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD, Am J Kidney Dis, 63, 713, 10.1053/j.ajkd.2014.01.416

Calvert, 1989, Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J Clin Oncol, 7, 1748, 10.1200/JCO.1989.7.11.1748

Puisset, 2014, Standardization of chemotherapy and individual dosing of platinum compounds, Anticancer Res, 34, 465

Graham, 2000, Clinical pharmacokinetics of oxaliplatin: a critical review, Clin Cancer Res, 6, 1205

Joannon, 2004, High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance, Pediatr Blood Cancer, 43, 17, 10.1002/pbc.20032

Mita, 2006, Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function, J Clin Oncol, 24, 552, 10.1200/JCO.2004.00.9720

Judson, 1998, Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694), Br J Cancer, 78, 1188, 10.1038/bjc.1998.652

Jannuzzo, 2004, The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women, Cancer Chemother Pharmacol, 53, 475, 10.1007/s00280-004-0774-5

Sharma, 2015, A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function, Cancer Chemother Pharmacol, 75, 87, 10.1007/s00280-014-2612-8

Skinner, 1993, Ifosfamide, mesna, and nephrotoxicity in children, J Clin Oncol, 11, 173, 10.1200/JCO.1993.11.1.173

Mould, 2010, Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development, BioDrugs, 24, 23, 10.2165/11530560-000000000-00000

Zhao, 2016, Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment, Br J Clin Pharmacol, 82, 696, 10.1111/bcp.12988

Nolin, 2015, A synopsis of clinical pharmacokinetic alterations in advanced CKD, Semin Dial, 28, 325, 10.1111/sdi.12374

Verbeeck, 2009, Pharmacokinetics and dosage adjustment in patients with renal dysfunction, Eur J Clin Pharmacol, 65, 757, 10.1007/s00228-009-0678-8

Nolin, 2006, Hemodialysis acutely improves hepatic CYP3A4 metabolic activity, J Am Soc Nephrol, 17, 2363, 10.1681/ASN.2006060610

Gibbons, 2008, Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group, J Clin Oncol, 26, 570, 10.1200/JCO.2007.13.3819

Jackson, 1982, Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin, Clin Pharmacol Ther, 32, 295, 10.1038/clpt.1982.163

Miller, 2009, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301, J Clin Oncol, 27, 1800, 10.1200/JCO.2008.20.0931

Canaud, 2019, Global prevalent use, trends and practices in haemodiafiltration, Nephrol Dial Transplant, 10.1093/ndt/gfz005

Tattersall, 2010, High-flux or low-flux dialysis: a positition statement following publication of the Membrane Permeability Outcome study, Nephrol Dial Transplant, 25, 1230, 10.1093/ndt/gfp626

Wall, 1996, Effective clearance of methotrexate using high-flux hemodialysis membranes, Am J Kidney Dis, 28, 846, 10.1016/S0272-6386(96)90384-4

Khosravan, 2010, Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function, J Clin Pharmacol, 50, 472, 10.1177/0091270009347868

Field, 2008, Part II: liver function in oncology: towards safer chemotherapy use, Lancet Oncology, 9, 1181, 10.1016/S1470-2045(08)70307-3

Peveling-Oberhag, 2013, Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study, Clin Ther, 35, 215, 10.1016/j.clinthera.2013.02.007

Juma, 1981, Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites, Eur J Clin Pharmacol, 19, 443, 10.1007/BF00548589

Field, 2008, Part I: liver function in oncology: biochemistry and beyond, Lancet Oncology, 9, 1092, 10.1016/S1470-2045(08)70279-1

Verbeeck, 2008, Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction, Eur J Clin Pharmacol, 64, 1147, 10.1007/s00228-008-0553-z

Rivory, 2002, Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response, Br J Cancer, 87, 277, 10.1038/sj.bjc.6600448

Morgan, 1995, Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update, Clin Pharmacokinet, 29, 370, 10.2165/00003088-199529050-00005

Horak, 2011, The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib, Cancer Chemother Pharmacol, 68, 1485, 10.1007/s00280-011-1611-2

de Jong, 2017, Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment, Leuk Lymphoma, 58, 185, 10.1080/10428194.2016.1189548

Shibata, 2013, Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study, Clin Cancer Res, 19, 3631, 10.1158/1078-0432.CCR-12-3214

Garattini, 2007, Pharmacokinetics in cancer chemotherapy, Eur J Cancer, 43, 271, 10.1016/j.ejca.2006.10.015

Verheijen, 2017, Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology, Clin Pharmacol Ther, 102, 765, 10.1002/cpt.787